期刊文献+

抗人前列腺干细胞抗原单克隆抗体可变区基因的5'RACE扩增及序列分析

Cloning and Analysis of the Sequence of Variable Region of An ti-Human PSCA Monoclonal Antibodies by 5'RACE
下载PDF
导出
摘要 目的:克隆并分析抗人前列腺干细胞抗原单克隆抗体轻链和重链的可变区基因。方法:从分泌抗人前列腺干细胞抗原单克隆抗体的杂交瘤细胞株中提取总RNA,根据小鼠IgG恒定区序列设计特异性引物,通过5′RACE法扩增其轻链和重链的可变区基因,克隆入pMD18-T载体,测序并分析其可变区序列。结果:3株抗人前列腺干细胞抗原单克隆抗体的重链可变区基因序列全长均为423 bp,编码141个氨基酸残基;轻链可变区基因序列全长均为393 bp,编码131个氨基酸残基;在GenBank中对氨基酸序列进行比对分析,均符合小鼠IgG可变区基因的特征;根据Kabat法则对3株抗体轻链和重链可变区氨基酸序列进行分析,确定了3个抗原互补决定区、4个框架区和前导肽。结论:通过5'RACE法得到了3株抗人前列腺干细胞抗原单克隆抗体轻链与重链可变区基因,为进一步研究抗体三维结构、人源化改造奠定了基础。 Objective: To clone and analyze the genes of light chain variable region(VL) and heavy chain vari-able region(VH) of monoclonal antibody(mAb) against human prostate stem cell antigen(PSCA). Methods: Total RNA was extracted from hybridoma cells which secrete mAb against human PSCA. Then VH and VL genes were amplified by 5'RACE with specific primers designed to match the high conservative nucleotide sequence of con-stant regions of mouse IgG. The PCR products were inserted into pMD18-T vector, followed by sequencing and analysis. Results: For each anti-PSCA mAb, VH gene contained 423 bp and encoded 141 amino acids, and the VL gene contained 393 bp and encoded 131 amino acids. They were homologous with the variable region of mouse IgG in GenBank. According to Kabat's rules, there were 4 framework regions, 3 complementarity determin-ing regions and a leader sequence in the VH and VL gene respectively. Conclusion: Acquisition of genes of the VH and VL of the anti-human PSCA mAbs will be a experimental basis for subsequent study of the mAb's 3D structure or humanization of antibody.
出处 《生物技术通讯》 CAS 2013年第4期457-461,共5页 Letters in Biotechnology
基金 国家自然科学基金(81172980)
关键词 人前列腺干细胞抗原 单克隆抗体 可变区序列 5'RACE human prostate stem cell antigen monoclonal antibody variable region 5'RACE
  • 相关文献

参考文献14

  • 1Reiter R E, Gu Z, Watabe T, et al. Prostate stem cell anti-gen: a cell surface marker overexpressed in prostate cancer[J]. Proc Natl Acad Sci USA, 1998,95(4):1735-1740.
  • 2Dannull J, Diener P A, Prikler L,et al. Prostate stem cell an-tigen is a promising candidate for immunotherapy of advancedprostate cancer[J]. Cancer Res, 2000,60(19):5522-5528.
  • 3Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell anti-gen(PSCA) expression increases with high gleason score, ad-vanced stage and bone metastasis in prostate cancer[J]. Onco-gene, 2000,19(10):1288-1296.
  • 4樊红艳,刘树玲,张晓鹏,易绍琼,房婷,董磊,于长明.抗人前列腺干细胞抗原单克隆抗体的制备及筛选[J].军事医学,2013,37(4):259-262. 被引量:1
  • 5Ruberti F, Cattaneo A, Bradbury A. The use of the RACEmethod to clone hybridoma cDNA when V region primers fail[J]. J Immunol Metho, 1994,173(1):33-39.
  • 6Bradbury A. Cloning hybridoma cDNA by RACE[M]//Konter-man R, Stefan D,eds. Antibody Engineering (Vol 1). BerlinHeidelberg: Springer-Verlag, 2010:15-20.
  • 7Larkin S E, Holmes S, Cree I A, et al. Identification of mark-ers of prostate cancer progression using candidate gene expres-sion[J]. Br J Cancer, 2012,106(1):157-165.
  • 8Leyton J V,Olafsen T, Lepin E J, et al. Humanized radioio-dinated minibody for imaging of prostate stem cell antigen-ex-pressing tumors[J]. Clin Cancer Res, 2008,14(22):7488-7496.
  • 9Zhang X, Yu C, Zhao J, et al. Vaccination with a DNA vac-cine based on human PSCA and HSP70 adjuvant enhancesthe antigen-specific CD8 * T-cell response and inhibits thePSCA* tumors growth in mice[J]. J Gene Med, 2007,9(8):715-726.
  • 10Ross S, Spencer S D, Holcomb I, et al. Prostate stem cell an- tigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate[J]. Cancer Res, 2002,62(9):2546-2553.

二级参考文献12

  • 1Reiter RE, Gu Z,Watabe T, et al. Prostate stem cell antigen: acell surface marker overexpressed in prostate cancer [ J ]. ProcNatl Acad Sci USA, 1998,95(4) : 1735 -1740.
  • 2Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen(PSCA) expression increases with high Gleason score, advancedstage and bone metastasis in prostate cancer [ J ]. Oncogene,2000,19(10) : 1288 - 1296.
  • 3Dannull J, Diener PA, Prikler L, et al. Prostate stem cell anti-gen is a promising candidate for immunotherapy of advanced pros-tate cancer[ J]. Cancer Res, 2000,60( 19) : 5522 -5528.
  • 4Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell anti-gen as therapy target ; tissue expression and in vivo efficacy of animmunoconjugate[ J]. Cancer Res, 2002,62(9) : 2546 -2553.
  • 5Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodina-ted minibody for imaging of prostate stem cell antigen-expressingtumors[ J]. Clin Cancer Res,2008,14(22) : 7488 -7496.
  • 6Zhang X,Yu C,Zhao J,et al. Vaccination with a DNA vaccinebased on human PSCA and HSP70 adjuvant enhances the anti-gen-specific CD8+ T-cell response and inhibits the PSCA+tumors growth in mice [ J ] ‘ J Gene Med, 2007 ,9(8) ; 715 -726.
  • 7Han KR, Seligson DB, Liu X,et al. Prostate stem cell antigenexpression is associated with Gleason score,seminal vesicle inva-sion and capsular invasion in prostate cancer[ J]. J Urol, 2004,171(3) : 1117-1121.
  • 8Zhao Z, Shen W. Prostate stem cell antigen (PSCA) expressionin human prostate cancer tissues and its potential role in prostatecarcinogenesis and progression of prostate cancer [ J ]. World JSurg Oncol, 2004,2: 13.
  • 9Lam JS, Yamashiro J, Shintaku IP, et al. Prostate stem cell an-tigen is overexpressed in prostate cancer metastases [ J ]. ClinCancer Res, 2005,11(7) : 2591 -2596.
  • 10Larkin SE, Holmes S, Cree IA, et al. Identification of markersof prostate cancer progression using candidate gene expression[J]. BrJ Cancer, 2012,106(1): 157 -165.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部